| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1753944708098226 |
| P698 | PubMed publication ID | 19144669 |
| P2093 | author name string | Wilhelm Kirch | |
| Christoph Schindler | |||
| Evgeny Idelevich | |||
| P2860 | cites work | 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. | Q22241393 |
| Long term pharmacotherapy for obesity and overweight: updated meta-analysis. | Q22242086 | ||
| Prevalence and Trends in Obesity Among US Adults, 1999-2000 | Q22253005 | ||
| Rimonabant for overweight or obesity | Q24244078 | ||
| Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus | Q24245173 | ||
| Long-term pharmacotherapy for obesity and overweight | Q24247723 | ||
| Pharmacological therapy of obesity: past, present, and future | Q28177035 | ||
| Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients | Q42642257 | ||
| Orlistat over the counter | Q42788151 | ||
| Long-term weight loss with sibutramine: a randomized controlled trial | Q43740082 | ||
| Orlistat inhibits dietary cholesterol absorption | Q43763133 | ||
| Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? | Q43913683 | ||
| Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial | Q44007390 | ||
| Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin | Q44043319 | ||
| Effects of orlistat on fat-soluble vitamins in obese adolescents | Q44069742 | ||
| The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial | Q44198041 | ||
| A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin | Q44262737 | ||
| Adiponectin and protection against type 2 diabetes mellitus | Q44290932 | ||
| Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials | Q44584072 | ||
| Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey | Q44677815 | ||
| Plasma adiponectin levels and risk of myocardial infarction in men. | Q44843420 | ||
| Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study | Q44883917 | ||
| Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. | Q45097301 | ||
| Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial | Q45142441 | ||
| Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials | Q45247023 | ||
| Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management | Q46388725 | ||
| Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial | Q46704823 | ||
| Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia | Q46807918 | ||
| Orlistat and sibutramine beyond weight loss | Q46956998 | ||
| Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group | Q47244827 | ||
| Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group | Q47284487 | ||
| Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study | Q47693449 | ||
| Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES). | Q53317326 | ||
| International trial of long-term dexfenfluramine in obesity. | Q53407808 | ||
| Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled | Q57384068 | ||
| Recognition and management of overweight and obesity in primary care in Germany | Q57384070 | ||
| Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians | Q28243500 | ||
| Valvular heart disease associated with fenfluramine-phentermine | Q28247282 | ||
| The emerging role of the endocannabinoid system in endocrine regulation and energy balance | Q28283398 | ||
| The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells | Q28575514 | ||
| Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery | Q29614192 | ||
| Drug treatments for obesity: orlistat, sibutramine, and rimonabant. | Q30359088 | ||
| Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial | Q31931766 | ||
| The efficacy and safety of sibutramine for weight loss: a systematic review | Q33202786 | ||
| Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. | Q33213285 | ||
| XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients | Q33974818 | ||
| Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients | Q33999230 | ||
| Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents | Q34002682 | ||
| Years of life lost due to obesity | Q34169086 | ||
| Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis | Q34169434 | ||
| Effects of Orlistat, a Lipase Inhibitor, on the Pharmacokinetics of Three Highly Lipophilic Drugs (Amiodarone, Fluoxetine, and Simvastatin) in Healthy Volunteers | Q34193869 | ||
| Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers | Q34379128 | ||
| Meta-analysis: pharmacologic treatment of obesity | Q34408897 | ||
| The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen | Q34479461 | ||
| Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial | Q34489294 | ||
| Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial | Q34494637 | ||
| Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study | Q34556870 | ||
| Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. | Q35596331 | ||
| The endocannabinoid system and its therapeutic exploitation | Q35876026 | ||
| Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice | Q36183802 | ||
| Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). | Q36242359 | ||
| The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension | Q36251751 | ||
| Opportunities and challenges for the development of pharmacological therapies for obesity treatment | Q36742647 | ||
| Drug treatment of the overweight patient | Q36820209 | ||
| Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials | Q37005419 | ||
| The obesity epidemic: pharmacological challenges | Q37135020 | ||
| The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? | Q37362674 | ||
| Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial | Q38391268 | ||
| Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study | Q40227593 | ||
| The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study | Q40749802 | ||
| Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials | Q40841364 | ||
| P433 | issue | 1 | |
| P921 | main subject | obesity | Q12174 |
| P304 | page(s) | 75-90 | |
| P577 | publication date | 2008-11-28 | |
| P1433 | published in | Therapeutic advances in cardiovascular disease | Q26842002 |
| P1476 | title | Current pharmacotherapeutic concepts for the treatment of obesity in adults | |
| P478 | volume | 3 |
| Q34231426 | A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys |
| Q35921532 | Allele-specific differences in activity of a novel cannabinoid receptor 1 (CNR1) gene intronic enhancer in hypothalamus, dorsal root ganglia, and hippocampus |
| Q84170976 | Beneficial impact of aerobic exercises on bone mineral density in obese premenopausal women under caloric restriction |
| Q37791137 | Cardiovascular Risk-Benefit Profile of Sibutramine |
| Q35205363 | Clinical and economic considerations of antiobesity treatment: a review of orlistat |
| Q47384909 | Effects of deoxynivalenol consumption on body weight and adiposity in the diet-induced obese mouse |
| Q36601724 | Metabolic rate regulation by the renin-angiotensin system: brain vs. body |
| Q21296814 | Pharmacotherapies for obesity: past, current, and future therapies |
| Q48473673 | Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE). |
| Q38130529 | The effect of antiobesity drugs on waist circumference: a mixed treatment comparison |
| Q92755085 | Three new polyoxygenated bergamotanes from the endophytic fungus Penicillium purpurogenum IMM 003 and their inhibitory activity against pancreatic lipase |
| Q37606027 | What are the risks and the benefits of current and emerging weight-loss medications? |
Search more.